Why the study?
Does spironolactone reduce urinary albumin excretion and left ventricular mass index in patients with type 2 diabetes and early nephropathy who show aldosterone escape during ACE inhibitor treatment?
Population
45 patients with type 2 diabetes and early nephropathy treated with an ACE inhibitor for 40 weeks, of whom…
Design
Cohort
Follow-up
24 weeks (for spironolactone phase)
Authors
Loading...
Spironolactone addition may lower albuminuria and LVMI without BP change in this cohort; hypothesis-generating and requires RCTs before practice change.
Does spironolactone reduce urinary albumin excretion and left ventricular mass index in patients with type 2 diabetes and early nephropathy who show aldosterone escape during ACE inhibitor treatment?
Adding spironolactone to ACE inhibitors in patients with type 2 diabetes and early nephropathy who experience aldosterone escape significantly reduces albuminuria and left ventricular mass.
Sato et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: